DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com

by · The Markets Daily

Stock analysts at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX – Get Free Report) in a report released on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

View Our Latest Analysis on DURECT

DURECT Price Performance

NASDAQ:DRRX opened at $0.85 on Friday. The firm has a market capitalization of $26.39 million, a P/E ratio of -1.39 and a beta of 1.01. DURECT has a one year low of $0.51 and a one year high of $1.88. The company’s 50-day simple moving average is $1.07 and its 200 day simple moving average is $1.29.

Institutional Trading of DURECT

A number of institutional investors have recently made changes to their positions in the stock. International Assets Investment Management LLC raised its holdings in shares of DURECT by 41.3% during the second quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,300 shares during the last quarter. Geode Capital Management LLC grew its position in DURECT by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 14,658 shares during the period. Finally, Richmond Brothers Inc. raised its stake in DURECT by 39.5% during the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock valued at $1,383,000 after buying an additional 303,670 shares during the last quarter. Hedge funds and other institutional investors own 28.03% of the company’s stock.

About DURECT

(Get Free Report)

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

Further Reading